Skip to main content
Displaying 154 of 2943 articles.
Mojsov is recognized for her discovery of the peptide hormone GLP-1, research that led to a new class of safe and highly effective drugs for type 2 diabetes as well as the treatment of obesity.

Jeffrey M. Friedman’s lab has discovered a mechanism to explain how leptin resistance works.

Most obese patients grow resistant to satiety signals from the hormone leptin. A new study shows that leptin sensitivity can be restored in mice, leading to weight loss.

Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID and Ebola, while also minimizing side effects and reducing the odds of drug resistance.

New findings on how past viral respiratory infections affect future, unrelated ones could lead to therapies for boosting general antiviral immunity—and potentially better pandemic preparedness.

New understanding of how the virus replicates could lead to new therapeutic targets for HBV.

Thomas Tuschl has devoted his career to making discoveries that bridge the gap between bench and business—and have resulted in entirely new classes of drugs.

Marraffini is honored for his pioneering research on the study of CRISPR-Cas systems.

New research suggests that the long sought-after environmental trigger for MS is a toxin produced by certain C. perfringens bacteria.

Birsoy is honored for groundbreaking research uncovering metabolic weaknesses of diseased cells, such as cancer, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.
View
View